FDA approves first generic Strattera for the treatment of ADHD

 
u s food and drug administration

News Release

Bookmark and Share

 

05/30/2017 04:49 PM EDT

The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

###


This email was sent to Email Address using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

This email was sent to bsamad2007.adnan@blogger.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

Comments

Popular Posts

Fwd: Claim "Climate law & governance" for your profile

Commissions Successfully

The State Department requires proof that you are the owner.

Reduced Payment!.

Your order requires immediate confirmation.

January 3nd Nоte (Оpen Up)

You’re four weeks away from more followers 📱

We have Your e-Wallet ready. Claim in 3hrs

Beneficiary countersignature modification